Medpace Q2 2021 revenue up 35.8% to $278.3M; net income $39.9M ($1.06 EPS)

Medpace Holdings, Inc.

2021-Q2 EPS reported $2.20 revenue$538,258,000

Net new business awards of $387.6M (+52.5% YoY) produced a 1.39x book-to-bill ratio.
Backlog grew 29.8% to $1.7B; revenue backlog conversion rate 17.1%.
EBITDA $47.9M (17.2% margin), up 36.9% YoY; GAAP net income margin 14.3%.
Direct costs $203.6M vs $148.4M; SG&A $27.0M vs $21.9M in prior-year quarter.
On a constant currency basis, organic revenue grew 34.4% and EBITDA grew 41.5%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.